Respiratorius AB (publ) (XSAT:RESP)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.875
-0.120 (-6.02%)
At close: Dec 4, 2025
-53.13%
Market Cap 14.70M
Revenue (ttm) n/a
Net Income (ttm) -7.12M
Shares Out 7.90M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,341
Average Volume 19,953
Open 1.990
Previous Close 1.995
Day's Range 1.875 - 1.990
52-Week Range 1.675 - 10.500
Beta 1.66
RSI 36.63
Earnings Date Nov 11, 2025

About Respiratorius AB

Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 1
Stock Exchange Spotlight Stock Market
Ticker Symbol RESP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.